Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
12.47
+0.10 (0.81%)
At close: Jun 27, 2025, 4:00 PM
13.10
+0.63 (5.05%)
After-hours: Jun 27, 2025, 7:04 PM EDT
Zymeworks Revenue
Zymeworks had revenue of $27.11M in the quarter ending March 31, 2025, with 170.29% growth. This brings the company's revenue in the last twelve months to $93.38M, up 85.05% year-over-year. In the year 2024, Zymeworks had annual revenue of $76.30M with 0.38% growth.
Revenue (ttm)
$93.38M
Revenue Growth
+85.05%
P/S Ratio
10.22
Revenue / Employee
$326,517
Employees
286
Market Cap
868.95M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 76.30M | 292.00K | 0.38% |
Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ZYME News
- 15 days ago - Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade) - Seeking Alpha
- 4 weeks ago - Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - GlobeNewsWire
- 5 weeks ago - Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - GlobeNewsWire
- 5 weeks ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference - GlobeNewsWire
- 7 weeks ago - Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline - Seeking Alpha